Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/49091
IS THERE A PLACE FOR MESENCHYMAL STROMAL CELL-BASED THERAPIES IN THE THERAPEUTIC ARMAMENTARIUM AGAINST COVID-19?
Pneumonia
Células estromais
Síndrome da angústia respiratória
SARS-CoV-2
Cell therapy
Mesenchymal stromal cells
Acute respiratory distress syndrome
SARS-CoV-2
Author
Silva, Kátia Nunes da
Gobatto, André Luiz Nunes
Ferro, Zaquer Suzana Munhoz Costa
Cavalcante, Bruno Raphael Ribeiro
Caria, Alex Cleber Improta
França, Luciana Souza de Aragão
Nonaka, Carolina Kymie Vasques
Lima, Fernanda de Macêdo
Pacheco, Miquéias Lopes
Rocco, Patricia Rieken Macêdo
Souza, Bruno Solano de Freitas
Gobatto, André Luiz Nunes
Ferro, Zaquer Suzana Munhoz Costa
Cavalcante, Bruno Raphael Ribeiro
Caria, Alex Cleber Improta
França, Luciana Souza de Aragão
Nonaka, Carolina Kymie Vasques
Lima, Fernanda de Macêdo
Pacheco, Miquéias Lopes
Rocco, Patricia Rieken Macêdo
Souza, Bruno Solano de Freitas
Affilliation
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Bahia, Brasil / D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Bahia, Brasil.
, Federal University of Bahia. Faculty of Medicine. Graduate Program in Medicine and Health. Salvador, BA, Brazil..
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
Federal University of Rio de Janeiro. Carlos Chagas Filho Institute of Biophysics. Laboratory of Pulmonary Investigation. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Carlos Chagas Filho Institute of Biophysics. Laboratory of Pulmonary Investigation. Rio de Janeiro, RJ, Brazil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil / Ministry of Science and Technology, and Innovation,COVID-19 Virus Network. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Bahia, Brasil / D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Bahia, Brasil.
, Federal University of Bahia. Faculty of Medicine. Graduate Program in Medicine and Health. Salvador, BA, Brazil..
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
Federal University of Rio de Janeiro. Carlos Chagas Filho Institute of Biophysics. Laboratory of Pulmonary Investigation. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Carlos Chagas Filho Institute of Biophysics. Laboratory of Pulmonary Investigation. Rio de Janeiro, RJ, Brazil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil / Ministry of Science and Technology, and Innovation,COVID-19 Virus Network. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Bahia, Brasil / D’Or Institute for Research and Education. Salvador, BA, Brazil / São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil.
Abstract
The COVID-19 pandemic, caused by the rapid global spread of the novel coronavirus (SARS-CoV-2), has caused
healthcare systems to collapse and led to hundreds of thousands of deaths. The clinical spectrum of COVID-19 is
not only limited to local pneumonia but also represents multiple organ involvement, with potential for systemic
complications. One year after the pandemic, pathophysiological knowledge has evolved, and many therapeutic
advances have occurred, but mortality rates are still elevated in severe/critical COVID-19 cases. Mesenchymal
stromal cells (MSCs) can exert immunomodulatory, antiviral, and pro-regenerative paracrine/endocrine actions and
are therefore promising candidates for MSC-based therapies. In this review, we discuss the rationale for MSC-based
therapies based on currently available preclinical and clinical evidence of safety, potential efficacy, and mechanisms
of action. Finally, we present a critical analysis of the risks, limitations, challenges, and opportunities that place MSCbased
products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce
the pandemic’s unmet medical needs.
Keywords in Portuguese
COVID-19Pneumonia
Células estromais
Síndrome da angústia respiratória
SARS-CoV-2
Keywords
COVID-19Cell therapy
Mesenchymal stromal cells
Acute respiratory distress syndrome
SARS-CoV-2
Share